Cargando…

Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis

BACKGROUND: In patients with heart failure (HF), randomized controlled trials (RCTs) of sodium-glucose transporter-2 inhibitors (SGLT-2is) have proven to be effective in decreasing the primary composite outcome of cardiovascular death and hospitalizations for HF. A recently published meta-analysis s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rivera, Frederick Berro, Tang, Vincent Anthony S., De Luna, Deogracias Villa, Lerma, Edgar V., Vijayaraghavan, Krishnaswami, Kazory, Amir, Shah, Nilay S., Volgman, Annabelle Santos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256233/ https://www.ncbi.nlm.nih.gov/pubmed/37305172 http://dx.doi.org/10.1016/j.ahjo.2023.100261

Ejemplares similares

HIV-Associated Nephropathy in 2022
por: Rivera, Frederick Berro, et al.
Publicado: (2022)

Redefining Heart Failure in Breast Cancer
por: Volgman, Annabelle Santos, et al.
Publicado: (2022)

Treatment of dyslipidemia in patients with type 2 diabetes
por: Vijayaraghavan, Krishnaswami
Publicado: (2010)

Resurgence of Urgent-Start Peritoneal Dialysis in COVID-19 and Its Application to Advanced Heart Failure
por: Nassiri, Amir Ahmad, et al.
Publicado: (2021)

Sex Differences in Mortality From COVID-19 Pandemic: Are Men Vulnerable and Women Protected?
por: Sharma, Garima, et al.
Publicado: (2020)

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
por: Krishnan, Anoushka, et al.
Publicado: (2023)

Editorial commentary: COVID-19 as a cardiovascular disease risk factor
por: Oktay, Ahmet Afşin, et al.
Publicado: (2022)

Social media for cardiovascular journals: State of the art review
por: Brown, Sherry-Ann, et al.
Publicado: (2021)

The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure
por: Ji, Peng‐juan, et al.
Publicado: (2023)

Class effects of SGLT2 inhibitors on cardiorenal outcomes
por: Kluger, Aaron Y., et al.
Publicado: (2019)

Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials
por: Lee, Mei-Chuan, et al.
Publicado: (2022)

Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Gager, Gloria M., et al.
Publicado: (2021)

Fluid overload as a major target in management of cardiorenal syndrome: Implications for the practice of peritoneal dialysis
por: Kazory, Amir
Publicado: (2017)

The War of Attrition on Diuretic Resistance: We Need to Open a Third Front
por: Kazory, Amir
Publicado: (2023)

Impact of the COVID-19 pandemic on cardiovascular disease mortality in a major metropolitan area
por: Kim, Yoo Jin, et al.
Publicado: (2022)

Commentary: Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
por: Qiu, Mei, et al.
Publicado: (2021)

Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?
por: Pitt, Bertram, et al.
Publicado: (2022)

Sex, Rhythm & Death: The effect of sexual activity on cardiac arrhythmias and sudden cardiac death
por: Dye, Cicely Anne, et al.
Publicado: (2022)

Women in Cardiology: Role of Social Media in Advocacy
por: Patel, Hena, et al.
Publicado: (2021)

Exploratory Review of the Role of Statins, Colchicine, and Aspirin for the Prevention of Radiation‐Associated Cardiovascular Disease and Mortality
por: Camara Planek, Maria Isabel, et al.
Publicado: (2020)

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
por: Saucedo-Orozco, Huitzilihuitl, et al.
Publicado: (2022)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
por: Frąk, Weronika, et al.
Publicado: (2023)

Sex Differences in the Age of Diagnosis for Cardiovascular Disease and Its Risk Factors Among US Adults: Trends From 2008 to 2017, the Medical Expenditure Panel Survey
por: Okunrintemi, Victor, et al.
Publicado: (2020)

Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
por: De Lorenzi, Andrea Beatriz, et al.
Publicado: (2023)

Sex Differences in Cardiovascular Disease and Cognitive Impairment: Another Health Disparity for Women?
por: Volgman, Annabelle Santos, et al.
Publicado: (2019)

SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis
por: Cardoso, Rhanderson, et al.
Publicado: (2021)

Synthetic marijuana and acute kidney injury: an unforeseen association
por: Kazory, Amir, et al.
Publicado: (2013)

Bilateral renal infarction: an uncommon presentation of fibromuscular dysplasia
por: Ayach, Taha, et al.
Publicado: (2013)

Natriuretic Peptides as Biomarkers for Congestive States: The Cardiorenal Divergence
por: Koratala, Abhilash, et al.
Publicado: (2017)

Pearls and Purple: The Dawn of a Modern Age
por: Tracy, Melissa, et al.
Publicado: (2021)

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

SGLT1: A Potential Drug Target for Cardiovascular Disease
por: Zhao, Mengnan, et al.
Publicado: (2023)

Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease
por: Shao, Shih-Chieh, et al.
Publicado: (2021)

Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes
por: Gronda, Edoardo G., et al.
Publicado: (2022)

Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials
por: Carvalho, Pedro E. P., et al.
Publicado: (2023)

Understanding the Mechanisms and Treatment of Heart Failure: Quantitative Systems Pharmacology Models with a Focus on SGLT2 Inhibitors and Sex-Specific Differences
por: Ndiaye, Jean François, et al.
Publicado: (2023)

SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
por: Talha, Khawaja M., et al.
Publicado: (2023)

Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
por: Rabizadeh, Soghra, et al.
Publicado: (2019)

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
por: Suzuki, Yuta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qn9s144om2nlkicjrjas7dgnft